文献库搜索 | GeneLibs

Li(H),Yang(X),Liu(L),Qin(Y),Song(Y),Yao(Y) Prenat Diagn 2026-08-00

...MYCN, and KIAA0825, with one incidental finding in PIK3CD. The diagnostic yield was significantly higher in the non-isol...

Gupta(R),Lakhanpal(S),Kumar(N),Nagraik(R),... Front Cell Dev Biol None

...MYCN amplification and ALK mutations have been extensively investigated, accumulating genomic and epigenomic evidence in...

Kato(R),Aoki(H),Toriuchi(K),Izumi(K),Nagas... Pediatr Res 2026-06-02

...MYCN-amplified and non-amplified cell lines. Combination treatment reduced cell numbers more effectively than either age...

Rasic(P),Samardzija(G),Djuricic(SM),Mitrov... Front Immunol None

...MYCN status, and prognostic risk group. The B7-H3 low/CD3 high immune phenotype identifies patients with markedly favora...

Yow(CX),Yeoh(S),Leen(E),Bayliss(R) Biosci Rep 2026-06-17

...MYCN oncogene is a hallmark of high-risk disease. MYCN protein is a transcription factor that promotes proliferation and...

Wusiman(R),Chang(Z),Yang(F),Lin(D),Xu(J) World J Surg Oncol 2026-07-06

...MYCN. This study revealed that LMNTD2-AS1 was significantly upregulated in ESCC tissues and cellular models. Downregulat...

Liang(J),Li(F),Ding(Z),Yan(B),Zhu(Y),Wang(... Rev Neurol 2026-06-26

...MYCN amplification status, patients were divided into amplification (MNA group) and non-amplified (MYCN-NA group) groups...

Montiel Equihua(C),Baxter(JS),Molenaar(JJ)... Br J Cancer 2026-07-09

...MYCN amplified or TP53 mutated; and Group 3 medulloblastoma, c-MYC amplified) and developing less-toxic therapies for go...

Guyot(C),Van de Velde(LA),Kainacher(L),Ruo... Cell Rep 2026-06-23

High-risk neuroblastoma (NB) is driven by the amplification of MYCN in conjunction with additional oncogenic mutations i...

Bhardwaj(S),Singh(J),Singh(S),Roy(C),Jangi... Neurooncol Pract 2026-02-00

...MYCN. Among the 12 cases, 7 were classified under the RTK-1 subtype, 3 under RTK2 subtype, and a case each under MYCN, p...